Injectable Melatonin (IPR-490)
Sepsis
Phase 2Active
Key Facts
About Pharmamel
Pharmamel is a clinical-stage biotech developing novel melatonin-based therapeutics for severe inflammatory and oxidative conditions. Its lead program targets sepsis, a life-threatening immune response to infection, and it holds a robust international patent portfolio covering formulations for sepsis, viral diseases, cancer, and mucositis. The company is currently in a pre-IPO phase, actively raising capital through a regulated platform to finance clinical development and pursue a public listing on the Spanish BME Scaleup market.
View full company profileTherapeutic Areas
Other Sepsis Drugs
| Drug | Company | Phase |
|---|---|---|
| Point of care multiplex sepsis test | EDX Medical | Launching |
| VB-001 | VST Bio | Pre-clinical |
| SIXTIDE | Sepsia Therapeutics | Pre-clinical |
| Ultrasensitive Sepsis Diagnostics | DIANA Biotechnologies | Development/Commercialization |
| EXO‑CD24 | Nano24med | Preclinical |